A retrospective, multinational, cross-sectional survey of real-world outcomes for patients with axial spondyloarthritis receiving subcutaneous infliximab
BMC Rheumatology 2025;9:139 Doi: 10.1186/s41927-025-00594-9
In this real-world study, Baraliakos, et al. SC IFX demonstrated clinical effectiveness in both
r- and nr-axSpA, with consistent results across diverse patient characteristics. Both physicians and patients reported high satisfaction with no new safety concerns. Authors assessed the real-world outcomes of CT-P13 SC (SC IFX) as treatment for both r- and
nr-axSpA.
This analysis suggests that SC IFX can be an effective, convenient, and well-tolerated treatment option for diverse axSpA patient populations.
Keywords:
